Back

Reversal of apixaban and rivaroxaban anticoagulation by andexanet alfa in ANNEXA-A&R as assessed by non-tissue factor (TF)-initiated thrombin generation independent of TF pathway inhibitor (TFPI)

25 August 2018 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Platelets, haemostasis and coagulation Thrombosis, Bleeding ESC Premium Access ESC Congress 2018

About the speaker

Photo
Doctor Genmin Lu

Portola Pharmaceuticals Inc, South San Francisco (United States of America)

9 More presentations in this session

Presentation thumbnail
Dyslipidemia associated oxidised ldl induces platelet hyperactivity through a cd36-dependent activation of pde3a
Doctor M. Berger (Aachen, DE)
Abstract Slides Video
Presentation thumbnail
Alterations in clot architecture associated with low fibrinolytic potential in acute myocardial infarction
Doctor N. Spinthakis (Torbay, GB)
Abstract Slides Video
Presentation thumbnail
Low- level confocal dual- pulse electrohydraulic shock wave therapy accompanied by tissue plasminogen activator and microbubbles administration for intracranial arterial recanalization
Doctor H. Mehrad (Tabriz, IR)
Presentation thumbnail
JNJ-9375, a novel exosite 1 thrombin inhibitor does not increase bleeding in a spontaneous gastrointestinal (GI) bleeding model in mice with a mutation of the Adenomatous polyposis coli (Apc) gene
Doctor M. Chintala (Spring House, US)
Abstract Slides Video
Presentation thumbnail
Pharmacological inhibition of S6K1 facilitates platelet activation by enhancing Akt phosphorylation
Doctor W. Gao (Shanghai, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Platelets, haemostasis and coagulation

The Event

Event poster

ESC Congress 2018

25 August - 29 August 2018

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources